Lataa...
Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells
BACKGROUND: Topotecan (TPT) is a therapeutic option for women with platinum-resistant or -refractory ovarian cancer. However, the dose-limiting toxicity of TPT is myelosuppression. This led us to seek a combination treatment to augment TPT anti-cancer activity in a cancer-targeted manner. Ovarian se...
Tallennettuna:
| Julkaisussa: | BMC Cancer |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4379550/ https://ncbi.nlm.nih.gov/pubmed/25884494 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1231-z |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|